External Innovation Think Tank (eITT) Exhibition 2020

Event eITT Keyvisual
External Innovation Think Tank (eITT) Exhibition 2020
 
Submit Feedback

 

We as the Innovation Think Tank - part of the Chief Technology Office of Siemens Healthineers – are happy to welcome you to our annual external Innovation Think Tank (eITT) Exhibition 2020. The event focuses on open innovation and co-creation in the area of healthcare by bringing together key stakeholders such as hospitals, research institutions, universities, start-ups and VCs.

The focus of this year's exhibition is to show the complete pathways for the most prominent diseases (e.g. coronary artery disease, cancer, diabetes etc.), the impact of COVID-19 on them and the possible solutions to solve these challenges. They are in the areas of digitalization, automation, new diagnostic and treatment methods, clinical innovation and process improvements in the healthcare system.

Due to the current COVID-19 pandemic and digitalization being one of the key strategies for Siemens Healthineers, we have modified the format of our ITT exhibition 2020 to a virtual recorded event which includes

  • Recorded speeches from experts and management representatives from Siemens Healthineers and ITT key collaboration partners showing what we did together in the last years, what our plans for the next year are and how interdisciplinary Innovation Think Tank methodology has been helping in addressing the complex challenges in healthcare (bringing experts, disciplines, locations and healthcare system stakeholders together).
  • Virtual tour of the ITT Office and lab giving an insight into our infrastructure, methodology and processes.
  • Projects in the following areas by ITT Fellows and members from ITT locations and collaborations worldwide
    • Facts and figures about 12 diseases, chosen based on top economic burden, social impact and mortality
    • How disease pathways get influenced by the challenges from COVID-19
    • Possible solutions to address those challenges in various disease pathways

This format allows you to have a look at the speeches of your choice at any time and disease content in the areas of your interest at any time as well as to share feedback with us.

Recorded Speeches from Experts and Management Representatives from Siemens Healthineers and ITT Key Collaboration Partners

Dr. Peter Schardt, Chief Technology Officer, Siemens Healthineers

Dr. Fatih Gül, Chief Operating Officer, Fakeeh University Hospital Dubai

Dr. Sonja Förster, Post Doctoral Researcher, ETH Zurich

Prof. James Moore JR, Bagrit Chair in Medical Device Design, Imperial College London

Ole Per Måløy, Managing Director Middle East and Southern & Eastern Africa, Siemens Healthineers & Dr. Mohaymen Abdelghany, CEO Al Zahra Hospital

Prof. Rafael Song, Associate Professor of Mechanical and Biomedical Engineering, New York University Abu Dhabi

Dr. Osama Abdullah, MRI Physicist, New York University Abu Dhabi

Andre Heinz, Head of Human Resources, Siemens Healthineers

Hannah Moon, Global Internship Advisor, Georgia Institute of Technology

Dr. Kong Jun, General Manager of SSME, Siemens Healthineers

Renato Buselli, Head of Latin America, Siemens Healthineers

Prof. Giovanni Cerri, President of the Innovation Board of HCFMUSP

Prof. Ata Akin, Dean of Engineering, Acibadem University Istanbul

Sevket On, Managing Director and President, Siemens Healthineers Canada

Dr. Stefan Henkel, Head of IT, Siemens Healthineers

Neşet Hikmet, Ph.D., Academic Director & Benjamin Schooley, Ph.D., Innovation Director & Dilek Akgun, RTTP, Operations Director, University of South Carolina ITT Lab

Enis Sonemel, Managing Director of Turkey, Siemens Healthineers

Prof. Burak Acar, Professor of Electrical and Electronics Engineering & Prof. Suzan Uskudarli, Computer Engineering Department, Boğaziçi University Istanbul

Ufuk Eren, Chief Executive Officer, Volitan Global

Prof. David Franklin, Professor for Neuromuscular Diagnostics, Technical University Munich

Prof. Michael Friebe, HealthTec Innovation Lab, Medical Faculty, Otto-von-Guericke-University Magdeburg

Steffen März, Chief Financial Officer and Managing Director & Dr. Roopika Menon, Head of Customer Management & Dr. Stefan Foser, Chief Technical Officer, NEO NewOncology

Prof. Dr. Georg Michelson, Senior Physician, Ophthalmology

Daniel Rinck, Innovation Manager and Head of Innovation Think Tank at Magnetic Resonance Imaging, Siemens Healthineers

Prof. Debasish Mishra, School of Bio-Sciences and Technology at Vellore Institute of Technology (VIT)

Prof. Sandeep Singh, Department of Cardiology, Executive Director, School of International Biodesign, All India Institute of Medical Sciences, New Delhi

Martin Hecht, Head of PLM at Mechatronic Products, Siemens Healthineers

Gassan Azem, Head of Computed Tomography Performance Product Line, Siemens Healthineers

  • Dr. Peter Schardt, Chief Technology Officer, Siemens Healthineers
  • Dr. Fatih Gül, Chief Operating Officer, Fakeeh University Hospital Dubai
  • Dr. Sonja Förster, Post Doctoral Researcher, ETH Zurich
  • Prof. James Moore JR, Bagrit Chair in Medical Device Design, Imperial College London
  • Ole Per Måløy, Managing Director Middle East and Southern & Eastern Africa, Siemens Healthineers & Dr. Mohaymen Abdelghany, CEO Al Zahra Hospital
  • Prof. Rafael Song, Associate Professor of Mechanical and Biomedical Engineering, New York University Abu Dhabi
  • Dr. Osama Abdullah, MRI Physicist, New York University Abu Dhabi
  • Andre Heinz, Head of Human Resources, Siemens Healthineers
  • Hannah Moon, Global Internship Advisor, Georgia Institute of Technology
  • Dr. Kong Jun, General Manager of SSME, Siemens Healthineers
  • Renato Buselli, Head of Latin America, Siemens Healthineers
  • Prof. Giovanni Cerri, President of the Innovation Board of HCFMUSP
  • Prof. Ata Akin, Dean of Engineering, Acibadem University Istanbul
  • Sevket On, Managing Director and President, Siemens Healthineers Canada
  • Dr. Stefan Henkel, Head of IT, Siemens Healthineers
  • Neşet Hikmet, Ph.D., Academic Director & Benjamin Schooley, Ph.D., Innovation Director & Dilek Akgun, RTTP, Operations Director, University of South Carolina ITT Lab
  • Enis Sonemel, Managing Director of Turkey, Siemens Healthineers
  • Prof. Burak Acar, Professor of Electrical and Electronics Engineering & Prof. Suzan Uskudarli, Computer Engineering Department, Boğaziçi University Istanbul
  • Ufuk Eren, Chief Executive Officer, Volitan Global
  • Prof. David Franklin, Professor for Neuromuscular Diagnostics, Technical University Munich
  • Prof. Michael Friebe, HealthTec Innovation Lab, Medical Faculty, Otto-von-Guericke-University Magdeburg
  • Steffen März, Chief Financial Officer and Managing Director & Dr. Roopika Menon, Head of Customer Management & Dr. Stefan Foser, Chief Technical Officer, NEO NewOncology
  • Prof. Dr. Georg Michelson, Senior Physician, Ophthalmology
  • Daniel Rinck, Innovation Manager and Head of Innovation Think Tank at Magnetic Resonance Imaging, Siemens Healthineers
  • Prof. Debasish Mishra, School of Bio-Sciences and Technology at Vellore Institute of Technology (VIT)
  • Prof. Sandeep Singh, Department of Cardiology, Executive Director, School of International Biodesign, All India Institute of Medical Sciences, New Delhi
  • Martin Hecht, Head of PLM at Mechatronic Products, Siemens Healthineers
  • Gassan Azem, Head of Computed Tomography Performance Product Line, Siemens Healthineers

More recorded speeches are coming soon

Virtual ITT Office and Lab Tour

Disease Pathways influenced by COVID-19

Acknowledgements

We would like to cordially thank all of you for your invaluable contributions for the annual external Innovation Think Tank Exhibition 2020:

  • Dr. Peter Schardt, Chief Technology Officer, Siemens Healthineers,
  • Dr. Fatih Gül, Chief Operating Officer, Fakeeh University Hospital Dubai
  • Dr. Sonja Förster, Post-Doctoral Researcher, ETH Zurich
  • Prof. James Moore JR, Bagrit Chair in Medical Device Design, Imperial College London
  • Ole Per Måløy, Managing Director Middle East and Southern & Eastern Africa, Siemens Healthineers
  • Prof. Rafael Song, Associate Professor of Mechanical and Biomedical Engineering, New York University Abu Dhabi
  • Dr. Osama Abdullah, MRI Physicist, New York University Abu Dhabi
  • Andre Heinz, Head of Human Resources, Siemens Healthineers
  • Hannah Moon, Global Internship Advisor, Georgia Institute of Technology
  • Dr. Kong Jun, General Manager of SSME, Siemens Healthineers
  • Renato Buselli, Head of Latin America, Siemens Healthineers
  • Prof. Giovanni Cerri, President of the Innovation Board of HCFMUSP
  • Prof. Ata Akin, Dean of Engineering, Acibadem University Istanbul
  • Sevket On, Managing Director and President, Siemens Healthineers Canada
  • Dr. Stefan Henkel, Head of IT, Siemens Healthineers
  • Prof. Dr. Jochen Hampe, Head of Gastroenterology and Hepatology at Carl Gustav Carus Dresden, Head of EKZF Institute Dresden
  • Neşet Hikmet, Ph.D., Academic Director & Benjamin Schooley, Ph.D., Innovation Director & Dilek Akgun, RTTP, Operations Director, University of South Carolina ITT Lab
  • Prof. Burak Acar, Professor of Electrical and Electronics Engineering & Prof. Suzan Uskudarli, Computer Engineering Department, Boğaziçi University Istanbul
  • Ufuk Eren, Chief Executive Officer, Volitan Global
  • Prof. David Franklin, Professor for Neuromuscular Diagnostics, Technical University Munich
  • Prof. Michael Friebe, HealthTec Innovation Lab, Medical Faculty, Otto-von-Guericke-University Magdeburg
  • Steffen März, Chief Financial Officer and Managing Director & Dr. Roopika Menon, Head of Customer Management & Dr. Stefan Foser, Chief Technical Officer, NEO NewOncology
  • Daniel Rinck, Innovation Manager and Head of Innovation Think Tank at Magnetic Resonance Imaging, Siemens Healthineers
  • Prof. Dr. Georg Michelson, Senior Physician, Ophthalmology
  • Prof. Debasish Mishra, School of Bio-Sciences and Technology at Vellore Institute of Technology (VIT)
  • Prof. Sandeep Singh, Department of Cardiology, Executive Director, School of International Biodesign, All India Institute of Medical Sciences, New Delhi
  • Martin Hecht, Head of PLM at Mechatronic Products, Siemens Healthineers
  • Gassan Azem, Head of Computed Tomography Performance Product Line, Siemens Healthineers
  • Dr. Mohammad Ali, Senior Resident Doctor at Department of Radiation Oncology, King George Medical University, India
  • Dr. Pooja Radhakrishna, Product Owner/System Engineer with the AT VSS team, Siemens Healthineers
  • Prof. Dr. İ. Haldun Müderrisoğlu, Dean of the Medical Faculty – Head of the Cardiology Department, Baskent Hospital
  • Assoc. Prof Uğur Abbas Bal, Department of Cardiology, Baskent Hospital
  • Asst. Prof. Emir Karaçağlar, Department of Cardiology, Baskent Hospital
  • Prof. Dr. Ufuk Can, Head of the Neurology Department, Baskent Hospital
  • Dr. Seda Kibaroğlu, Department of Neurology, Baskent Hospital
  • Prof. Dr. Müşerref Şule Akçay, Head of the Pulmonary Diseases Department, Baskent Hospital
  • Prof. Dr. Ayşe Elif Küpeli, Department of Pulmonary Diseases, Baskent Hospital
  • Prof. Dr. Neslihan Başçıl Tütüncü, Head of the Endocrinology and Metabolic Diseases Department, Baskent Hospital
  • Prof. Dr. Özden Altundağ, Head of the Department of Medical Oncology, Baskent Hospital
  • Prof. Dr. Adnan Torgay, Chief Physician of Başkent University Ankara Hospital, Baskent HospitalHanife Altuntaş, Management Secretary, Baskent Hospital
  • Arzu Fırlarer, Coordinator at Baskent ITT, Baskent Hospital
  • Aylin Dedeoğlu, Baskent ITT – Entrepreneurship & Prototyping Lab Expert, Baskent Hospital
  • Dr. Adil Khan Yusuf Zai, Innovation fellow, School of International Biodesign (Stanford India Biodesign), AIIMS & IIT-Delhi
  • Balamurugan S, Innovation Fellow, School of International Biodesign, AIIMS - New Delhi
  • Enis Sonemel, Managing Director of Turkey, Siemens Healthineers

Impressions from the eITT Exhibition 2019

Twelve diseases that afflict mankind

It begins with unborn children: how can expectant mothers reduce their child’s risk of disease? How can we improve the diagnosis, treatment and the handling of breast cancer, for example? The “Innovation Think Tank” (ITT) has for the first time developed complex treatment plans for twelve diseases which pose the biggest risk to mankind. The core idea: technological innovation. Some treatment plans were presented internationally at the annual external ITT Exhibition on July 11, 2019.
One in eight women will develop breast cancer in their lifetime. According to the WHO, it is estimated that 627,000 women died from breast cancer in 2018 – that is approximately 15% of all cancer deaths among women. For the patients themselves and their social circle the disease is tragic and traumatic, much the same as many other sometimes fatal diseases. “We want to change that. That's why at ITT we’re analyzing the most difficult points in the treatment paths of the deadliest and most costly diseases over the entire life and disease cycle of humans. This begins in the womb and ends with aftercare,” explains Sultan Haider, founder and head of ITT at Healthineers at this year's Innovation Think Tank exhibition (eITT 2019) in Erlangen.

Basis for joint research and development
He addressed the 130 participants from around 40 international organizations: “We are aware of the problems with the prevention, diagnosis, treatment and aftercare of diseases like breast cancer. Action must be taken, and that’s exactly what we are doing: our response is technological innovations which will help patients, doctors and others involved to prevent the disease or to halt its progress. The technology is available! The important thing now is that all of us - technology companies and start-ups, research institutes and universities - work together to make it operational.” The health system is also groaning under the weight of the worst diseases, says Haider, so much of it is also about reducing the financial burden along the whole treatment pathway. Again, new technologies are the key here.

How do technological innovations help?
They are designed to save time, and therefore money, improve the patient experience and enable access to important information for the doctors, hospital administration or governmental bodies. Specifically, it is about three fields of technology: digital technologies, such as the Internet of Medical Things (IoMT), the 5G mobile communication standard, artificial intelligence or Blockchain which we are combining in the treatment pathways with automated solutions – focusing here on robotics and sensors – and clinical innovations such as new diagnostic methods, digital pathology or minimally invasive procedures for example.

Which diseases are being looked at?
Haider’s ITT team have identified twelve diseases whose global burden – both social and economic – is particularly high:

1. Lung Cancer; 2. Breast Cancer; 3. Leukemia; 4. Chronic Obstructive Pulmonary Disease (COPD); 5. Tuberculosis (TB); 6. Multiple Sclerosis (MS); 7. Alzheimer’s Disease; 8. Parkinson’s Disease; 9. Coronary Artery Disease; 10. Stroke; 11. Diabetes; 12. Traumatic Injuries
 

Around 150 employees in different ITT teams around the world have already been working for several years to build an enormous and broad database of these diseases. The data comes from, among sources, health organizations and scientific journals. In order to develop the matrix-like, highly complex treatment pathways they followed the life and the progression of the patient with all the different interfaces to their social and medical environment.

Haider
“And we’re not just focusing on the time when medical care would usually start, but going back to the very beginning, before somebody who may later become a patient has even been born. Because this is where we lay the foundation for our health.” Sultan Haider

What does a treatment pathway look like?

Working prototype of a portable ultrasound device for remote diagnosis.
Each treatment pathway includes predefined stations through which the patient moves. In the case of breast cancer, for example, these are: prenatal, prevention, symptoms, diagnosis, rehabilitation and outpatient care, which includes reintegration into everyday life after inpatient cancer treatment.

“We carefully defined each individual station, from the risk factors for a fetus, through screening and other prevention measures to monitoring progress and the most difficult points.” Sultan Haider

One example:

  • The situation: A patient can sense changes in her breast.
  • Points of difficulty: She does not go to a regular check, perhaps because she is worried about the somewhat uncomfortable situation during the examination or the examination itself.
  • Possible solutions: An app (digital innovation) reminds her to get her breasts examined. She receives a portable ultrasound device (clinical innovation) for remote diagnosis, which instructs the patient on how to screen her breast herself at home. In addition, if the woman has difficulty detecting changes in her breast an intelligent sensor-equipped bra (digital innovation) could also help her.

The audience are appreciative of ITT's extensive analysis and treatment pathways. Peter Schardt, Chief Technology Officer and responsible for the Technology & Innovation (TI) organization, to which ITT also belongs, is impressed:

“The treatment pathways provide the unique basis for a comprehensive collaboration that will benefit all of us and the patient. As a technology supplier, for example, we can gain valuable information through a mutual, open exchange in order to adapt our products and solutions to the requirements of our customers.” Peter Schardt
"Through its global infrastructure, deep data analytics, workshops and ultimately events like the one today, the ITT creates an innovation-friendly environment and a sheer inexhaustible knowledge pool that we should all use. Thanks very much to the ITT team!” Peter Schardt
dummy
“With jointly defined goals, we can succeed in showing the 'big picture' of a disease, in which experts with very different skillsets can participate. It's great to work with such a dedicated and global team to figure out the key challenges and work together to find a solution.” Sultan Haider

Here you can find an example of a care plan – breast cancer: Download PDF 4.2 MB

For more and detailed information about the disease and projects please feel free to contact us:
innovationthinktank.team@siemens-healthineers.com
 

Team
Sultan Haider
Prof. Friebe
Prof. Akin
Mr. Maloey
Gerd Höfner
Experts
Expert panel discussion
eITT exhibition
eITT
Dr. Peter Schardt
Awards

About Innovation Think Tank

Proactively drive innovation to improve human life

Innovation Think Tank (ITT) is a part of the Chief Technology Office of Siemens Healthineers. Driven by the need of interdisciplinary and self-sustaining infrastructures which are accessible for the entire departments, ITT was established in 2005. The global ITT infrastructure includes multiple innovation labs across Germany, China, India, Turkey, the United States, United Arab Emirates, and United Kingdom, addressing projects from 23 Siemens locations. The program success and recognition led to the establishment of ITT locations at prestigious healthcare institutions and universities.

ITT was founded and is headed globally by Prof. Sultan Haider, who is a Principal Key Expert at Siemens Healthineers (SHS), a title awarded to him by SHS Managing Board in the year 2008 for his outstanding innovation track record which includes the establishment of 32 innovation activity locations and over 500 inventions and patents filed. Furthermore, Prof. Haider has been awarded honorary directorships, professorships and has developed innovation infrastructures and implemented innovation management certification programs for top institutions.

Innovation Think Tank Facts and Figures

  • 32 ITT activity locations established (ITT Labs/ ITT Certification Programs)
  • 86 ITT certification programs conducted worldwide
  • 2500 + R&D and strategy projects experience
  • Filed more than 1,500 inventions and patents
  • 200 ITT Fellowships offered annually. Engaged with over 2500 researchers, professors and students from over 150 universities in 38 countries
  • 900 + hospital visits conducted for various healthcare requirement engineering projects

Vision

Proactively drive innovation to improve human life

Mission

Utilizing global self-sustaining innovation infrastructures to accelerate identifying and implementing new business opportunities


Compartilhe esta página: